|
|
| (12 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{drugbox
| | #redirect:[[Amikacin sulfate]] |
| | IUPAC_name = (2''S'')-4-amino-N-[(2''S'',3''S'',4''R'',5''S'')-5-amino-2-<br>[(2''S'',3''R'',4''S'',5''S'',6''R'')-4-amino-3,5-dihydroxy-<br>6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2''R'',3''R'',<br>4''S'',5''R'',6''R'')-6-(aminomethyl)-3,4,5-trihydroxy-<br>oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-<br>butanamide
| |
| | image = Amikacin.png
| |
| | CAS_number = 37517-28-5
| |
| | ATC_prefix = D06
| |
| | ATC_suffix = AX12
| |
| | ATC_supplemental = {{ATC|J01|GB06}}, {{ATC|S01|AA21}}
| |
| | PubChem = 441188
| |
| | DrugBank = APRD00550
| |
| | C = 22 | H = 43 | N = 5 | O = 13
| |
| | molecular_weight = 585.603 g/mol
| |
| | bioavailability =
| |
| | protein_bound = 0-11%
| |
| | metabolism =
| |
| | elimination_half-life = 2-3 hours
| |
| | excretion = [[Kidney|Renal]]
| |
| | pregnancy_AU = D
| |
| | pregnancy_US = C
| |
| | legal_UK = POM
| |
| | legal_US = Rx-only
| |
| | routes_of_administration = [[Intramuscular injection|Intramuscular]], [[Intravenous therapy|intravenous]]
| |
| }}
| |
| {{SI}}
| |
| {{CMG}}
| |
| | |
| {{EH}}
| |
| | |
| ==Overview==
| |
| '''Amikacin''' is an [[aminoglycoside]] [[antibiotic]] used to treat different types of [[bacteria|bacterial]] [[infection]]s. Amikacin works by binding to the bacterial [[30S]] [[ribosome|ribosomal]] subunit, causing misreading of [[mRNA]] and leaving the bacterium unable to synthesize [[protein]]s vital to its growth.
| |
| | |
| ==Administration==
| |
| Amikacin may be administered once or twice a day but must be given by the [[intravenous]] or [[intramuscular]] route, which tends to be painful. There is no oral form available. Dosage must be adjusted in people with [[kidney failure]].
| |
| | |
| ==Uses==
| |
| Amikacin is most often used for treating severe, hospital-acquired infections with [[multidrug resistance|multidrug resistant]] [[Gram negative]] bacteria such as ''[[Pseudomonas aeruginosa]]'', ''[[Acinetobacter]]'', and ''[[Enterobacter]]''.
| |
| | |
| Amikacin may be combined with a [[beta-lactam]] antibiotic for [[empiric therapy]] for people with [[neutropenia]] and [[fever]].
| |
| | |
| ==Side effects==
| |
| Side effects of amikacin are similar to other aminoglycosides. [[Nephrotoxicity|Kidney damage]] and [[ototoxicity|hearing loss]] are the most important effects. Because of this potential, blood levels of the drug and markers of kidney function ([[creatinine]]) may be monitored.
| |
| | |
| ==References==
| |
| * Edson RS, Terrell CL. ''The aminoglycosides.'' Mayo Clin Proc. 1999 May;74(5):519-28. Review. PMID 10319086
| |
| | |
| {{Antibiotics and chemotherapeutics for dermatological use}}
| |
| {{AminoglycosideAntiBiotics}}
| |
| {{SIB}}
| |
| [[Category:Aminoglycoside antibiotics]]
| |
| | |
| [[es:Amikacina]]
| |
| [[ru:Амикацин]]
| |
| [[th:อะมิกาซิน]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WS}}
| |